Status:
TERMINATED
Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome
Lead Sponsor:
Yale University
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Polycystic Ovary Syndrome
Hypertension
Eligibility:
FEMALE
18-35 years
Phase:
EARLY_PHASE1
Brief Summary
Women with androgen excess polycystic ovary syndrome (AE-PCOS) leads to hypertension.
Detailed Description
Our scientific premise is that in AE-PCOS women, the androgen-dominant hormonal milieu causes BP increases via sympathetic activation, vasoconstriction and renal sympathetic nervous system activation....
Eligibility Criteria
Inclusion
- Clinical Diagnosis of Polycystic Ovary Syndrome
- Able to inject study drug
- Able to swallow pills
- Controls:
- Diagnosis of Insulin resistance
Exclusion
- Any woman that does not fit the inclusion criteria
- Males
Key Trial Info
Start Date :
December 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT04327934
Start Date
December 1 2017
End Date
June 30 2022
Last Update
February 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The John B Pierce Laboratory
New Haven, Connecticut, United States, 06519